Bipartisan Commission on Biodefense  By  cover art

Bipartisan Commission on Biodefense

By: Bipartisan Commission on Biodefense
  • Summary

  • The Bipartisan Commission on Biodefense is a privately funded entity established in 2014 to provide for a comprehensive assessment of the state of U.S. biodefense efforts and to issue recommendations that will foster change. From 2014-2015, the Commission convened four public meetings in Washington, DC on biological threat awareness, prevention and protection, surveillance and detection, and response and recovery. Current and former Members of Congress, former Administration officials, state and local representatives, thought leaders, and other experts provided their perspectives on current biodefense efforts, including strengths, weaknesses, and opportunities. While much good work has been achieved toward biodefense, these meetings have revealed systemic challenges in the enterprise designed to protect Americans from biological events. The Commission continues to advocate for uptake of these recommendations at the highest levels of American government, through additional meetings, reports, and other activities, and is the only such body of bipartisan, former high-level policymakers to do so.
    Copyright 2021 All rights reserved.
    Show more Show less
activate_primeday_promo_in_buybox_DT
Episodes
  • Masters of the Air: Overcoming Airborne Pathogens Indoors
    Jul 30 2024

    In this meeting, the Bipartisan Commission on Biodefense will explore: (1) how the federal government currently addresses indoor air quality; (2) new scientific and technological advances for indoor air quality; and (3) how enhancing indoor air quality can help prevent the spread of pathogens.

    Learn more here: https://biodefensecommission.org/events/masters-of-the-air-overcoming-airborne-pathogens-indoors/

    Show more Show less
    3 hrs and 3 mins
  • A Tribute to Senator Lieberman with the Release of the 2024 National Blueprint for Biodefense
    May 14 2024

    We all lost a visionary leader and friend with the unexpected passing of Senator Joe Lieberman, who along with Governor Tom Ridge co-chaired the Bipartisan Commission on Biodefense for ten years.

    His death came just as the Commission was preparing to release our 2024 National Blueprint for Biodefense: Immediate Action Needed to Defend Against Biological Threats. Senator Lieberman, who worked tirelessly to defend Americans against biological threats, was a driving force behind this report. So, it is only fitting that we host a special tribute to Senator Lieberman as we publicly release the new National Blueprint for Biodefense.

    The Bipartisan Commission on Biodefense (formerly the Blue Ribbon Study Panel on Biodefense) was established in 2014 to provide a comprehensive assessment of the state of United States biodefense efforts and to issue recommendations that foster change. Subsequently, the Commission has briefed White House Administrations (including then Vice President Biden); testified before Congress; convened numerous meetings with experts; released 12 reports; produced the graphic novel Germ Warfare; and mobilized biodefense conversations and actions in the private and public sectors.

    In its  2015 bipartisan report,  A National Blueprint for Biodefense: Leadership and Major Reform Needed to Optimize Efforts, the Commission described biological threats to the Nation and made 33 recommendations to optimize US efforts to prevent, deter, prepare for, detect, respond to, attribute, recover from, and mitigate intentionally introduced, accidentally released, and naturally occurring biological events. Many recommendations from this report have been taken up by the government, including the National Biodefense Strategy, a federal biodefense budget crosscut by the Office of Management and Budget, and the recent Biodefense Posture Review by the Department of Defense.

    The world continues to experience rising threats from offensive biological weapons programs, lab accidents, and outbreaks affecting our national security. There have been burgeoning biotechnological advances in medical countermeasures (e.g., antibiotics, antivirals, vaccines, diagnostics) yet huge gaps in prevention, deterrence, preparedness, detection, response, attribution, recovery, and mitigation still remain. The federal government must address gaps in the US biodefense enterprise. Nine years after its seminal report, the Commission is releasing the 2024 National Blueprint on Biodefense with specific recommendations for government leaders in Congress and the Administration to strengthen the federal government’s biodefense posture.

    Learn more here: A Tribute to Senator Lieberman with the Release of the 2024 National Blueprint for Biodefense - Bipartisan Commission on Biodefense (biodefensecommission.org)

    Show more Show less
    1 hr and 23 mins
  • Meeting the Moment: Biodefense Policy, Procurement, and Public Health
    Dec 11 2023

    This meeting was recorded on Tuesday, December 5, 2023. Find more information about this meeting here: Meeting the Moment: Biodefense Policy, Procurement, and Public Health - Bipartisan Commission on Biodefense (biodefensecommission.org)

    As the Nation continues to endure the consequences of recent pandemics, and with continued interest in biological weapons by nation states and other enemies, the federal government has an opportunity to address vulnerabilities in the biodefense enterprise. At this meeting, titled Meeting the Moment: Biodefense Policy, Procurement, and Public Health, the Commission intends to further explore : (1) biodefense policies and activities at the Department of Defense; (2) federal stockpile evaluation and decision-making for smallpox medical countermeasures; (3) needed authorities of the Department of Health and Human Services, including the Centers for Disease Control and Prevention; and (4) biodefense leadership.

    Show more Show less
    3 hrs and 32 mins

What listeners say about Bipartisan Commission on Biodefense

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.